Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of osimertinib combined with anti-VEGF therapy ramucirumab in managing leptomeningeal metastasis in EGFR-mutant NSCLC: a case report and literature review.

Journal of cardiothoracic surgery - 6 Mar 2026

Tsai Yueh-Hsun, Weng Yu-Shiou, Huang Tsai-Wang

Abstract excerpt

BACKGROUND: Leptomeningeal metastasis (LM) is a severe complication of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), associated with limited treatment options and poor prognosis. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), has demonstrated central nervous system (CNS) efficacy, while ramucirumab, a VEGFR-2 inhibitor, may enhance drug penetration and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Indoles

Share to Meningeal Neoplasms

Share to Piperazines

Share to Pyrimidines

Share to Vascular Endothelial Growth Factor A

Source

Open in PubMed Open full text

Identifiers

PMID: 41792787
DOI: 10.1186/s13019-026-03923-2
PMCID: PMC13220362

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of osimertinib combined with anti-VEGF therapy ramucirumab in managing leptomeningeal metastasis in EGFR-mutant NSCLC: a case report and literature review.PMID 41792787Read ↗

Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report.Semantic proximity Read ↗

Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.Semantic proximity Read ↗

Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM).Semantic proximity Read ↗

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis.Semantic proximity Read ↗

Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI.Semantic proximity Read ↗

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.Semantic proximity Read ↗

Leptomeningeal Metastases in Non-small Cell Lung Cancer: Optimal Systemic Management in NSCLC With and Without Driver Mutations.Semantic proximity Read ↗

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.Semantic proximity Read ↗

Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies.Semantic proximity Read ↗

Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis.Semantic proximity Read ↗

Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.